뒤로
Arbutus Biopharma Corp(ABUS) 가격
ABUS 주가 차트
ABUS 수입
Arbutus Biopharma Corp
$4.06
-13.61%
$-0.64
종가: Jan 16, 16:00:00 GMT-5
$4.06
0%
$0
애프터마켓: Jan 16, 20:00:00 GMT-5
최신 수익 결과: Q3 '25
보고됨: 2025-11-13
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
ABUS의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Arbutus Biopharma Corp ABUS의 지난 분기 매출 실적은 어땠나요?
Arbutus Biopharma Corp의 매출 추정치는 얼마인가요?
Arbutus Biopharma Corp의 수익 품질 점수는 얼마인가요?
Arbutus Biopharma Corp는 언제 수익을 보고하나요?
Arbutus Biopharma Corp의 예상 수익은 얼마인가요?
Arbutus Biopharma Corp은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$4.7
시가
$3.93
일일 범위
$3.68 - $4.2
52주 범위
$2.71 - $5.1
거래량
8.5M
평균 거래량
1.2M
EPS(TTM)
-0.22
배당수익률
--
시가총액
$780.8M
ABUS란 무엇인가요?
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. The company is headquartered in Warminster, Pennsylvania and currently employs 44 full-time employees. The company went IPO on 2010-11-13. The firm is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.